公开(公告)号：WO2022204406A1

公开(公告)日：2022-09-29

申请号：PCT/US2022/021748

申请日：2022-03-24

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： ISABELLA, Vincent, M. ,  LUBKOWICZ, David ,  JAMES, Michael

IPC: A61K35/74 ,  A61P3/00 ,  A61K38/43 ,  C12N15/75 ,  C07K14/195 ,  A61K48/00

Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

公开(公告)号：WO2021207306A1

公开(公告)日：2021-10-14

申请号：PCT/US2021/026106

申请日：2021-04-07

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： GAO, Jian-Rong ,  KURTZ, Caroline ,  SOKOLOVSKA, Anna ,  LI, Ning

IPC: A61K39/12 ,  C12N7/00 ,  A61K39/215

Abstract: Modified microorganisms, pharmaceutical compositions thereof, and methods of preventing and treating the coronavirus disease 2019 (COVID-19) are disclosed.

公开(公告)号：WO2019232415A1

公开(公告)日：2019-12-05

申请号：PCT/US2019/034969

申请日：2019-05-31

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： MILLER, Paul, F. ,  ISABELLA, Vincent, M. ,  FALB, Dean ,  KOTULA, Jonathan, W. ,  DAGON, Yossi

IPC: A61K31/404 ,  A61P7/06 ,  A61P9/00 ,  A61K35/74 ,  A61P11/00 ,  A61P35/00

Abstract: The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts. The invention also provides pharmaceutical compositions comprising the genetically engineered bacteria, and methods of modulating and treating disorders associated with excess ammonia and inflammation in the gut and the liver, including, for example, hepatic encephalopathy, NASH/NAFLD, HCV, and Huntington's disease, in a subject, comprising administering the engineered bacterium to the subject.

公开(公告)号：WO2018237198A1

公开(公告)日：2018-12-27

申请号：PCT/US2018/038840

申请日：2018-06-21

Applicant: SYNLOGIC OPERATING COMPANY, INC. ,  SYNLOGIC, INC. ,  FALB, Dean ,  FISHER, Adam B. ,  ISABELLA, Vincent M. ,  KOTULA, Jonathan W. ,  LUBKOWICZ, David ,  MILLER, Paul F. ,  MILLET, Yves ,  ROWE, Sarah Elizabeth

Inventor： FALB, Dean ,  FISHER, Adam B. ,  ISABELLA, Vincent M. ,  KOTULA, Jonathan W. ,  LUBKOWICZ, David ,  MILLER, Paul F. ,  MILLET, Yves ,  ROWE, Sarah Elizabeth

IPC: C07K14/245 ,  A61K35/74 ,  C12N9/06 ,  C12N9/88 ,  C07K14/005

Abstract: Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.

公开(公告)号：WO2023044479A1

公开(公告)日：2023-03-23

申请号：PCT/US2022/076648

申请日：2022-09-19

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： BRENNAN, Aoife ,  KURTZ, Caroline ,  PUURUNEN, Marja

IPC: A61K38/16 ,  A61P3/02 ,  A61K48/00 ,  C12N15/00 ,  A61K35/74 ,  A61K38/44 ,  A61K38/51

Abstract: Methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

公开(公告)号：WO2022032084A1

公开(公告)日：2022-02-10

申请号：PCT/US2021/044923

申请日：2021-08-06

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： LI, Ning

IPC: C12P7/56 ,  C12N1/20 ,  C12N15/52

Abstract: The present disclosure provides recombinant bacteria for production of D-lactate and/or L-lactate. Pharmaceutical compositions and methods of treating diseases are also included in the present invention.

公开(公告)号：WO2021146394A1

公开(公告)日：2021-07-22

申请号：PCT/US2021/013398

申请日：2021-01-14

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： JAMES, Michael ,  CASTILLO, Mary, Joan ,  WONG, Tiffany ,  LI, Ning

IPC: C12N15/70 ,  C12N15/52 ,  C07K14/245

Abstract: The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient' s internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding an improved leucine catabolism enzyme with higher activity and/or specificity for leucine over other branched chain amino acids, such as isoleucine or valine. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of leucine, isoleucine, and/or valine using the pharmaceutical compositions disclosed herein.

公开(公告)号：WO2022146718A1

公开(公告)日：2022-07-07

申请号：PCT/US2021/063976

申请日：2021-12-17

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： ADOLFSEN, Kristin ,  GREISEN, Per ,  CALLIHAN, Isolde ,  LAWRENCE, Adam ,  SPOONAMORE, James ,  KONIECZKA, Jay ,  MONAHAN, Catherine ,  ISABELLA, Vincent ,  LUBKOWICZ, David

IPC: C12N9/88 ,  A61K35/74 ,  C12N1/21 ,  C12R1/19

Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

公开(公告)号：WO2021242897A1

公开(公告)日：2021-12-02

申请号：PCT/US2021/034314

申请日：2021-05-26

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： LI, Ning ,  GAO, Jian-Rong ,  BERGERON, Christopher, George

IPC: C12N15/52 ,  C12N15/70 ,  C12N15/74 ,  A61K35/74 ,  C12N9/0016 ,  C12N9/1077 ,  C12N9/1085 ,  C12N9/88 ,  C12N9/90 ,  C12P17/10 ,  C12Y104/01019 ,  C12Y204/02018 ,  C12Y205/01054 ,  C12Y401/01048 ,  C12Y401/01074 ,  C12Y401/03027 ,  C12Y402/0102

Abstract: The present disclosure provides recombinant bacteria for production of indole-3 -acetic acid (IAA). Pharmaceutical compositions and methods of treating diseases are also included.

公开(公告)号：WO2021242798A1

公开(公告)日：2021-12-02

申请号：PCT/US2021/034137

申请日：2021-05-26

Applicant: SYNLOGIC OPERATING COMPANY, INC.

Inventor： LI, Ning

IPC: A61K35/66 ,  A61P31/00 ,  A61P37/02 ,  A61K2039/523 ,  A61K2039/6006 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/001104 ,  A61K39/215 ,  C07K14/005 ,  C07K14/71 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/569 ,  C07K2319/00 ,  C07K2319/035 ,  C12N1/20 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12R2001/19

Abstract: Recombinant microorganisms, pharmaceutical compositions thereof, and methods of protein display on the cell surface of the microorganisms are disclosed.